MCID: RBL001
MIFTS: 62

Rubella

Categories: Eye diseases, Fetal diseases, Infectious diseases, Liver diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 44 Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention

MalaCards based summary : Rubella, also known as german measles, is related to mumps and acute disseminated encephalomyelitis, and has symptoms including fever, conjunctivitis and headache. An important gene associated with Rubella is MOG (Myelin Oligodendrocyte Glycoprotein), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and skin.

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 77 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)
# Related Disease Score Top Affiliating Genes
1 mumps 32.0 HLA-DPB1 HLA-DRB1 IFNAR2 IL10RB TNF
2 acute disseminated encephalomyelitis 31.9 HLA-B HLA-DQB1 HLA-DRB1 IL10 MOG
3 tetanus 30.7 CD40LG IL10 IL4
4 myelitis 30.6 HLA-DPB1 MOG TNF
5 pertussis 30.6 CALM1 IL10 TNF
6 arthritis 30.6 HLA-DQB1 HLA-DRB1 IL10 TNF
7 optic neuritis 30.5 HLA-DRB1 MOG TNF
8 poliomyelitis 30.5 IL10 IL4 TNF
9 neuritis 30.4 IL4 MOG TNF
10 juvenile rheumatoid arthritis 30.4 HLA-DPB1 HLA-DRB1 TNF
11 pneumonia 30.2 CD40LG IL10 TNF
12 cytomegalovirus infection 30.2 HLA-A HLA-B TNF
13 uveitis 30.2 HLA-B IL10 IL4 TNF
14 toxoplasmosis 30.1 CD40LG HLA-DQB1 IL10 IL4 TNF
15 herpes zoster 29.9 HLA-A HLA-B IL10
16 lupus erythematosus 29.9 CALR CD40LG IL10 TNF
17 rheumatic fever 29.9 HLA-DRB1 IL10 TNF
18 chlamydia 29.9 IL10 IL4 TNF
19 diabetes mellitus 29.9 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
20 recurrent respiratory papillomatosis 29.8 HLA-DQB1 HLA-DRB1
21 multiple sclerosis 29.7 HLA-DQB1 HLA-DRB1 IL10 IL4 MOG TNF
22 human immunodeficiency virus infectious disease 29.7 IL10 TNF TRIM5
23 intermediate uveitis 29.7 HLA-B IL10 TNF
24 complex regional pain syndrome 29.7 HLA-B IL10 TNF
25 myocarditis 29.6 CD40LG HLA-B HLA-DQB1 TNF
26 vasculitis 29.6 CD40LG HLA-B TNF
27 acquired immunodeficiency syndrome 29.6 HLA-B IL10 TNF
28 inflammatory bowel disease 29.5 IL10 IL10RB IL4 TNF
29 hematopoietic stem cell transplantation 29.4 HLA-A HLA-B IL10 TNF
30 rheumatic disease 29.3 CD40LG HLA-B HLA-DRB1 IL10 TNF
31 rheumatoid arthritis 29.1 CD40LG HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
32 human immunodeficiency virus type 1 29.1 HLA-A HLA-B IL10 TNF TRIM5
33 asthma 29.1 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL4
34 panuveitis 29.1 HLA-A HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
35 aplastic anemia 29.0 HLA-A HLA-B HLA-DRB1 IL4 TNF
36 colitis 28.9 IL10 IL10RB IL4 TNF
37 systemic lupus erythematosus 28.8 CALR CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
38 autoimmune disease 28.8 CD40LG HLA-DQB1 HLA-DRB1 IL10 IL4 MOG
39 malaria 28.7 CD40LG HLA-A HLA-B HLA-DRB1 IL10 IL4
40 congenital rubella 12.8
41 rubella panencephalitis 12.2
42 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 12.1
43 measles 11.8
44 congenital toxoplasmosis 11.3
45 gianotti crosti syndrome 11.3
46 microcephaly 11.2
47 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
48 immunodeficiency 45 11.0
49 congenital intrauterine infection-like syndrome 11.0
50 togaviridae disease 11.0

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12
  • fever
  • conjunctivitis
  • headache
  • lymphadenopathy
  • joint pains
  • rash on the face which spreads to the trunk

UMLS symptoms related to Rubella:


fever, pruritus, exanthema

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
2 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3 Liver Extracts Phase 4
4 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
8
Tetracycline Approved, Vet_approved Phase 3,Phase 1,Phase 2 60-54-8 5353990
9
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
10
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
11
Petrolatum Approved, Investigational Phase 3 8009-03-8
12
Podophyllin Approved Phase 3 9000-55-9
13
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
14
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
15
Lactitol Investigational Phase 3,Phase 2 585-86-4, 585-88-6 493591
16
Cobalamin Experimental Phase 3 13408-78-1 6857388
17 taxane Phase 3
18 Somatomedin B Phase 3
19 Hemagglutinins Phase 3
20 Anti-Infective Agents Phase 3,Phase 1,Phase 2
21 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
22 Vitamin B 12 Phase 3
23 Vitamin B12 Phase 3
24 PENTA Phase 3,Phase 2
25 Protective Agents Phase 3,Phase 2
26 Micronutrients Phase 3
27 Nutrients Phase 3
28 retinol Phase 3
29 Vitamins Phase 3
30 Trace Elements Phase 3
31 Antioxidants Phase 3
32 Retinol palmitate Phase 3
33 Dermatologic Agents Phase 3
34 Antineoplastic Agents, Phytogenic Phase 3
35 Insulin, Globin Zinc Phase 3
36 Keratolytic Agents Phase 3
37 insulin Phase 3
38
Altretamine Approved Phase 2 645-05-6 2123
39
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
40
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
41
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
42
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
43
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
44
Mycophenolic acid Approved Phase 2 24280-93-1 446541
45
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
46
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
47
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
48 Fibrinolytic Agents Phase 2
49 Anticoagulants Phase 2
50 Antineoplastic Agents, Immunological Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 164)
# Name Status NCT ID Phase Drugs
1 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Unknown status NCT03071575 Phase 4
2 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
3 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Unknown status NCT01770119 Phase 4
4 Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Completed NCT03680417 Phase 4
5 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
6 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
7 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
8 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
9 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
10 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
11 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
12 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
13 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
14 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
15 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
16 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
17 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
18 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
19 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
20 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
21 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
22 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
23 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
24 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
25 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
26 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
27 MMR at 6 Months Trial Not yet recruiting NCT03780179 Phase 4
28 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
29 Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Unknown status NCT03148990 Phase 2, Phase 3
30 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
31 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
32 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
33 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
34 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
35 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
36 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
37 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
38 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
39 Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III) Completed NCT03713359 Phase 3
40 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
41 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
42 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
43 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
44 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
45 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
46 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
47 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
48 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
49 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
50 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

20
Skin

MalaCards organs/tissues related to Rubella:

42
Testes, Skin, Eye, Brain, Heart, Lymph Node, T Cells

Publications for Rubella

Articles related to Rubella:

(show top 50) (show all 3630)
# Title Authors Year
1
Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. ( 30831578 )
2019
2
Last cases of rubella and congenital rubella syndrome in Spain, 1997-2016: The success of a vaccination program. ( 30454948 )
2019
3
Clinical manifestations of congenital rubella syndrome: A review of our experience in Vietnam. ( 30503658 )
2019
4
50 Years Ago in The Journal of Pediatrics: Maternal and Congenital Rubella before 1964: Frequency, Clinical Features, and Search for Isoimmune Phenomena. ( 30684990 )
2019
5
Comparison of two commercial ELISA kits for detection of rubella specific IgM in suspected congenital rubella syndrome cases and rubella IgG antibodies in a serosurvey of pregnant women. ( 30782464 )
2019
6
Congenital B-cell Acute Lymphoblastic Leukemia with Congenital Rubella Infection. ( 30806367 )
2019
7
Predicting congenital rubella syndrome in Japan, 2018-2019. ( 30807870 )
2019
8
Aniridia: A Rare Manifestation Of Congenital Rubella Syndrome. ( 30868799 )
2019
9
Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. ( 30814030 )
2019
10
Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. ( 30833160 )
2019
11
Will dual Japanese encephalitis and measles-rubella vaccination hinder measles and rubella eradication? ( 30833161 )
2019
12
Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. ( 30317494 )
2019
13
Antiviral immunity in chronic lymphocytic leukemia measured by anti-rubella antibody. ( 30659789 )
2019
14
Risk factors associated with accelerated rubella-IgG antibody loss in previously vaccinated,treatment-naïve juvenile Systemic Lupus Erythematosus patients: a prospective study. ( 30614217 )
2019
15
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study. ( 30843921 )
2019
16
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. ( 30849175 )
2019
17
Successes and challenges for preventing measles, mumps and rubella by vaccination. ( 30852425 )
2019
18
Measles and rubella seroprevalence in a population of young adult blood donors, France 2013. ( 30869022 )
2019
19
Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey. ( 30898393 )
2019
20
Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016. ( 30904317 )
2019
21
Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey. ( 30905529 )
2019
22
Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. ( 30666071 )
2019
23
Relationship Between Media Coverage and Measles-Mumps-Rubella (MMR) Vaccination Uptake in Denmark: Retrospective Study. ( 30672743 )
2019
24
Measles and rubella seroimmunity in newly arrived adult immigrants in Sweden. ( 30676125 )
2019
25
Measles, mumps, and rubella: A cross-sectional study of susceptibility to vaccine-preventable diseases among young people in India. ( 30705481 )
2019
26
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial. ( 30724658 )
2019
27
Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement. ( 30758772 )
2019
28
Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants. ( 30765170 )
2019
29
Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. ( 30765242 )
2019
30
Long-term protection against varicella with two-dose combination measles-mumps-rubella-varicella vaccine. ( 30765245 )
2019
31
The Efficacy and Safety of Intralesional Immunotherapy with Measles, Mumps, Rubella Virus Vaccine for the Treatment of Common Warts in Adults. ( 30775294 )
2019
32
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. ( 30785357 )
2019
33
The immunomodulatory effects of measles-mumps-rubella (MMR) vaccination on persistence of heterologous vaccine responses. ( 30791143 )
2019
34
Health Departments' Experience With Mumps Outbreak Response and Use of a Third Dose of Measles, Mumps, and Rubella Vaccine. ( 30807465 )
2019
35
Use of FTA® cards to transport throat swabs and oral fluid samples for molecular detection and genotyping of measles and rubella viruses. ( 30814262 )
2019
36
Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba. ( 30817853 )
2019
37
Clinical value of enzyme immunoassay that detects rubella-specific immunoglobulin M immediately after disease onset. ( 30549103 )
2019
38
Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders. ( 30607663 )
2019
39
Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma. ( 30680653 )
2019
40
Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision. ( 30701339 )
2019
41
Validation of monoplex assays detecting antibodies against Corynebacterium diphtheriae and Clostridium tetani toxins, Rubella virus and Parvovirus B19 for incorporation into Multiplex Serology. ( 30703462 )
2019
42
Determination of rubella virus-specific humoral and cell-mediated immunity in pregnant women with negative or equivocal rubella-specific IgG in routine screening. ( 30711798 )
2019
43
Low anti-rubella antibody levels in public facilities staff in Tokyo. ( 30723000 )
2019
44
Evaluation of the Abbott ARCHITECT™ cytomegalovirus IgM/IgG, rubella IgM/IgG, and syphilis treponemal antibodies enzyme immunoassays in a mother and child health center population. ( 30738692 )
2019
45
Clinical Manifestations, Prognosis And Vaccination Status Of Patients With Rubella Virus-Associated Uveitis. ( 30771336 )
2019
46
Antifungal Phenylpropanoid Glycosides from Lippia rubella. ( 30817148 )
2019
47
First report of the genomic characterization of rubella viruses circulating in Cameroon. ( 30822356 )
2019
48
A case of adult rubella in Japan. ( 30825652 )
2019
49
Erratum: Diagnosis of rubella virus using antigen-conjugated Au@Pt nanorods as nanozyme probe [Corrigendum]. ( 30863060 )
2019
50
Transposable elements drive rapid phenotypic variation in Capsella rubella. ( 30877258 )
2019

Variations for Rubella

Expression for Rubella

Search GEO for disease gene expression data for Rubella.

Pathways for Rubella

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CALM1 CALR CD40LG HLA-A HLA-B HLA-DPB1
2
Show member pathways
13.41 CALM1 CALR CD40LG HLA-A HLA-B HLA-DPB1
3
Show member pathways
12.94 CALM1 CALR HLA-A HLA-B IFNAR2 IL10RB
4
Show member pathways
12.91 CALM1 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
5
Show member pathways
12.59 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB IL4
6 12.54 C1QBP CD40LG IL10 IL4 TNF
7
Show member pathways
12.52 CALM1 HLA-A HLA-B IFNAR2 IL4 TNF
8
Show member pathways
12.46 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNAR2
9
Show member pathways
12.46 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
10
Show member pathways
12.42 CALM1 CD40LG IL10 IL4 TNF
11
Show member pathways
12.41 CALM1 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNAR2
12
Show member pathways
12.34 IFNAR2 IL10 IL10RB IL4
13
Show member pathways
12.34 CALM1 CD40LG HLA-DQB1 HLA-DRB1
14 12.32 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
15
Show member pathways
12.27 HLA-A HLA-B IFNAR2 IL10 IL4 TNF
16 12.2 CALM1 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB
17
Show member pathways
12.18 CALM1 HLA-DPB1 HLA-DQB1 HLA-DRB1
18
Show member pathways
12.18 CALM1 CALR CD40LG HLA-A HLA-B HLA-DPB1
19 12.15 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
20
Show member pathways
12.13 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB
21 12.11 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
22 11.93 IL10 IL4 TNF
23 11.92 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL4 TNF
24 11.91 IL10 IL4 TNF
25
Show member pathways
11.91 HLA-A HLA-DRB1 IL4
26
Show member pathways
11.89 HLA-DPB1 HLA-DQB1 HLA-DRB1
27 11.87 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
28 11.86 HLA-DPB1 HLA-DQB1 HLA-DRB1
29
Show member pathways
11.78 CALM1 CD40LG IL4 TNF
30 11.74 IL10 IL4 TNF
31 11.72 CALM1 IL10 TNF
32 11.71 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
33 11.68 IL10 IL4 TNF
34
Show member pathways
11.68 CALM1 HLA-A IFNAR2 TNF
35 11.63 CD40LG IL10 IL4
36 11.55 IL10 IL10RB IL4 TNF
37 11.5 CD40LG IL10 TNF
38 11.34 IL10 IL10RB TNF
39 11.29 HLA-DRB1 IL10 IL4 TNF
40 11.19 CALR HLA-A HLA-B
41 11.18 CD40LG IL10 IL4 TNF

GO Terms for Rubella

Cellular components related to Rubella according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.85 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 LST1
2 external side of plasma membrane GO:0009897 9.8 CALR CD40LG HLA-DRB1 MOG TNF
3 cell surface GO:0009986 9.76 C1QBP CALR CD40LG HLA-A HLA-B HLA-DPB1
4 trans-Golgi network membrane GO:0032588 9.71 HLA-DPB1 HLA-DQB1 HLA-DRB1
5 phagocytic vesicle membrane GO:0030670 9.69 CALR HLA-A HLA-B
6 endocytic vesicle membrane GO:0030666 9.63 HLA-DPB1 HLA-DQB1 HLA-DRB1
7 transport vesicle membrane GO:0030658 9.61 HLA-DPB1 HLA-DQB1 HLA-DRB1
8 MHC class I protein complex GO:0042612 9.52 HLA-A HLA-B
9 clathrin-coated endocytic vesicle membrane GO:0030669 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
10 MHC class II protein complex GO:0042613 9.43 HLA-DPB1 HLA-DQB1 HLA-DRB1
11 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
12 intracellular GO:0005622 9.25 CALR
13 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
14 plasma membrane GO:0005886 10.27 C1QBP CALM1 CD40LG HLA-A HLA-B HLA-DPB1
15 Golgi apparatus GO:0005794 10.02 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1 LST1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.91 IFNAR2 IL10RB TRIM22 TRIM5
2 cytokine-mediated signaling pathway GO:0019221 9.91 IFNAR2 IL10 IL10RB IL4 TNF
3 viral process GO:0016032 9.88 C1QBP HLA-B HLA-DRB1 MOG TRIM22 TRIM5
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 CD40LG TNF TRIM22 TRIM5
5 response to virus GO:0009615 9.85 IFNAR2 TNF TRIM22
6 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.84 HLA-DPB1 HLA-DQB1 HLA-DRB1
7 response to organic substance GO:0010033 9.83 CALR IL10 TNF
8 B cell differentiation GO:0030183 9.83 CD40LG IL10 IL4
9 T cell receptor signaling pathway GO:0050852 9.83 HLA-DPB1 HLA-DQB1 HLA-DRB1 MOG
10 type I interferon signaling pathway GO:0060337 9.81 HLA-A HLA-B IFNAR2
11 immune system process GO:0002376 9.8 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 LST1
12 positive regulation of T cell proliferation GO:0042102 9.79 CD40LG HLA-DPB1 IL4
13 regulation of immune response GO:0050776 9.77 CD40LG HLA-A HLA-B IL4 MOG
14 positive regulation of DNA-binding transcription factor activity GO:0051091 9.76 IL10 TNF TRIM22 TRIM5
15 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
16 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
17 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.67 CALR HLA-A HLA-B
18 negative regulation of interleukin-12 production GO:0032695 9.65 C1QBP IL10
19 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.65 HLA-A HLA-B
20 negative regulation of interferon-gamma production GO:0032689 9.65 C1QBP HLA-DRB1 IL10
21 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
22 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.63 HLA-A HLA-B
23 positive regulation of dendritic cell chemotaxis GO:2000510 9.63 C1QBP CALR
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 IL4
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
26 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.61 CALR HLA-A HLA-B
27 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.6 HLA-DQB1 HLA-DRB1
28 protection from natural killer cell mediated cytotoxicity GO:0042270 9.59 HLA-A HLA-B
29 regulation of immunoglobulin secretion GO:0051023 9.58 CD40LG TNF
30 regulation of isotype switching GO:0045191 9.58 IL10 IL4
31 type 2 immune response GO:0042092 9.57 IL10 IL4
32 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.55 HLA-DQB1 HLA-DRB1
33 antigen processing and presentation GO:0019882 9.55 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
34 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
35 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
36 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TRIM22
37 immune response GO:0006955 9.44 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DQB1 HLA-DRB1
2 cytokine activity GO:0005125 9.26 CD40LG IL10 IL4 TNF
3 complement component C1q binding GO:0001849 9.16 C1QBP CALR
4 peptide antigen binding GO:0042605 9.02 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1

Sources for Rubella

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....